About

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Lupus patients given hope of remission in groundbreaking trial

Microscope

UCB and Biogen announce positive Phase 3 results of dapirolizumab pegol in SLE from the PHOENYCS GO study

Lupus Therapy Essentials 2024 Update

Steering Committee